Patent US2272546A successfully refreshed from Google Patents.
Patent US5814620A successfully refreshed from Google Patents.
US5814620A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Inhibition of neovascularization using vegf-specific oligonucleotides
Assignee: Boston Children's Hospital
•
Filing: 1995-07-12
•
Granted: 1998-09-29
•
Expires: 2015-07-12
Abstract
Abstract Disclosed are methods of reducing neovascularization and of treating various disorders associated with neovascularization. These methods include administering to a tissue or subject a synthetic oligonucleotide specific for vascular endothelial growth factor nucleic acid effective in inhibiting the expression of vascular endothelial growth factor.
Inventors
- 👤 Gregory S. Robinson
- 👤 Lois Elaine Hodgson Smith
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 11:59
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C12N15/1136; A; A61; A61P; A61P17/00; A61P27/00; A61P27/02; A61P35/00; A61P43/00; A61P7/00; A61P9/00; A61P9/10; A61K; A61K38/00; C12N2310/00; C12N2310/30; C12N2310/31; C12N2310/312; C12N2310/3125; C12N2310/314; C12N2310/315; C12N2310/316; C12N2310/317; C12N2310/32; C12N2310/321; C12N2310/35; C12N2310/352; C12N2310/3521; C12N2310/50; C12N2310/53
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
47 words
A method of treating diabetic retinopathy comprising the step of intravitreally administrating to a subject afflicted with diabetic retinopathy a therapeutic amount of an oligonucleotide specific for vascular endothelial growth factor nucleic acid and effective in inhibiting the expression of vascular endothelial growth factor in the retina.
Claim 2
Independent Claim
47 words
A method of treating diabetic retinopathy comprising the step of intravitreally administrating to a subject afflicted with diabetic retinopathy a therapeutic amount of an oligonucleotide specific for vascular endothelial growth factor nucleic acid and effective in inhibiting the expression of vascular endothelial growth factor in the retina.
Claim 3
Dependent Claim
10 words
The method of claim 1 wherein the oligonucleotide is modified.
Claim 4
Dependent Claim
36 words
The method of claim 2 wherein the modified oligonucleotide has at least one internucleotide linkage selected from the group consisting of alkylphosphonates, phosphorothioates, phosphorodithioates, alkylphosphonothioates, phosphoramidates, phosphate esters, carbamates, acetamidate, carboxymethyl esters, carbonates, and phosphate triesters.
Claim 5
Dependent Claim
16 words
The method of claim 3 wherein the modified oligonucleotide has at least one phosphorothioate internucleotide linkage.
Claim 6
Dependent Claim
18 words
The method of claim 1 wherein the modified oligonucleotide comprises a ribonucleotide, a deoxyribonucleotide, or a combination thereof.
Claim 7
Dependent Claim
15 words
The method of claim 5 wherein the modified oligonucleotide comprises at least one 2'-O-alkylated ribonucleotide.
Claim 8
Dependent Claim
19 words
The method of claim 1 wherein the modified oligonucleotide is from about 14 to about 28 nucleotides in length.
Claim 9
Dependent Claim
18 words
The method of claim 7 wherein the modified oligonucleotide is about 15 to about 25 nucleotides in length.
References Cited (Backward Citations)
WO1995004142A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-09-28 | 2002-03-30 | 2002-09-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-09-28 | 2006-03-30 | 2006-09-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-09-28 | 2010-03-30 | 2010-09-29 | $7700.00 | Window Closed / Lapsed |